Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | XIAP | P98170 | 1/20 | 0.46 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9975069 | 0.87 | SMN1; SMN2 (0.53) | SMN1; SMN2CYP2C19NPC1RAB9AXIAP | |
| SCHEMBL9973496 | 0.86 | SMN1; SMN2 (0.51) | SMN1; SMN2CYP2C19NPC1RAB9AXIAP | |
| SCHEMBL9973491 | 0.81 | XIAP (0.53) | XIAPBIRC2 | |
| SCHEMBL25408531 | 0.80 | FKBP1A (0.51) | SMN1; SMN2CYP2C19NPC1RAB9AXIAP | |
| SCHEMBL14227553 | 0.80 | SMN1; SMN2 (0.49) | SMN1; SMN2CYP2C19NPC1RAB9AXIAP | |
| SCHEMBL25408533 | 0.80 | FKBP1A (0.51) | SMN1; SMN2CYP2C19NPC1RAB9AXIAP | |
| SCHEMBL13453701 | 0.79 | SMN1; SMN2 (0.53) | SMN1; SMN2CYP2C19NPC1RAB9AXIAP | |
| SCHEMBL4701802 | 0.79 | SMN1; SMN2 (0.52) | SMN1; SMN2CYP2C19NPC1RAB9AHTT | |
| SCHEMBL5494667 | 0.78 | SMN1; SMN2 (0.57) | SMN1; SMN2CYP2C19NPC1RAB9AHTT | |
| SCHEMBL16382728 | 0.77 | SMN1; SMN2 (0.55) | SMN1; SMN2CYP2C19NPC1RAB9AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8202902-B2 | Bivalent SMAC mimetics and the uses thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-06-19 | — | — | US | disclosed |
| US-20090123480-A1 | BIVALENT SMAC MIMETICS AND THE USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-05-14 | — | — | US | disclosed |
| US-20080089896-A1 | Bivalent SMAC mimetics and the uses thereof | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080089896-A1 | Bivalent SMAC mimetics and the uses thereof | BID, BAD, BIRC2 | SMN1; SMN2 193/4885CYP2C19 4875/4885NPC1 4724/4885 |
| US-20090123480-A1 | BIVALENT SMAC MIMETICS AND THE USES THEREOF | BID, BAD, BIRC2 | SMN1; SMN2 193/4885CYP2C19 4875/4885NPC1 4724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.